| Elacestrant studied in …STUDIED_INderived35 of 35show fewer |
|---|
| → studied in | NCT06075953Phase 2 · recruiting DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment · 35 trials list this drug (25 active) | — | — | Intraductal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06120283Phase 1 · recruiting BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors · 35 trials list this drug (25 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06923527Phase 2 · recruiting Circulating Tumor DNA · 35 trials list this drug (25 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05512364Phase 3 · recruiting Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06492616Phase 3 · recruiting A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07766018Phase 2 · recruiting A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05386108Phase 1/Phase 2 · recruiting Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer · 35 trials list this drug (25 active) | — | — | Neoplasm,Neoplasm by Site,Breast Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07222215Phase 2 · recruiting PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · 35 trials list this drug (25 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06382948Phase 3 · recruiting Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06691035Phase 1 · active not recruiting Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer · 35 trials list this drug (25 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07753954Phase 2 · not yet recruiting Medical Imaging to Re-evaluate Elacestrant Clinical Usage · 35 trials list this drug (25 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06638307Phase 1 · recruiting A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07242352Phase 3 · recruiting Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC · 35 trials list this drug (25 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05618613Phase 1/Phase 2 · terminated Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07209449Phase 2 · recruiting A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer · 35 trials list this drug (25 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07563595recruiting Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05573126Phase 1/Phase 2 · recruiting Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05563220Phase 1/Phase 2 · active not recruiting Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07198724Phase 1/Phase 2 · recruiting ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm,HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07634601Phase 2 · not yet recruiting Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer · 35 trials list this drug (25 active) | — | — | Endometrial Carcinoma,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07612215Phase 1/Phase 2 · recruiting Elacestrant in Advanced Triple Positive Breast Cancer · 35 trials list this drug (25 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07467772Phase 2 · recruiting Ph 2 Elacestrant in ER Positive Uterine Sarcomas · 35 trials list this drug (25 active) | — | — | Endometrioid Stromal Sarcoma,PEComa,Uterine Corpus Adenosarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05596409Phase 2 · active not recruiting ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05982093Phase 2 · recruiting Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04791384Phase 1/Phase 2 · terminated Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05963997Phase 1/Phase 2 · completed A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07159451Phase 2 · recruiting A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03778931Phase 3 · completed Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07005882Phase 2 · not yet recruiting Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy · 35 trials list this drug (25 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06938711Phase 1/Phase 2 · withdrawn A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06126575Phase 1 · completed A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function · 35 trials list this drug (25 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06544577unknown Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04797728early Phase 1 · completed Elacestrant in Preoperative Setting, a Window of Opportunity Study · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm,Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02338349Phase 1 · completed A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer · 35 trials list this drug (25 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02650817Phase 1 · completed Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer · 35 trials list this drug (25 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |